Connecticut-based NanoViricides, Inc. (NYSE MKT: NNVC) is a
development stage company working on what it considers to be the next great
advance in immunotherapeutics: nanoviricide biomimetic technology.
A nanoviricide is a unique antiviral agent designed to fool a
virus into attaching to it in the same way that a virus normally attaches to
the receptors of a cell surface. Once the virus is attached, the nanoviricide
wraps around the virus, causing the virus to lose its surface proteins, which
are used to bind to cells. The nanoviricide goes on to dismantle and destroy
the virus without immune system assistance. What virus a nanoviricide goes
after is programmed into the nanoviricide.
The company is developing virus-specific nanoviricide drug
candidates against influenza, HIV/AIDS, cold sores and herpes infection, viral
eye diseases, and dengue viruses, and its candidates are demonstrating high
levels of drug effectiveness. Product candidates are based on TheraCour®
technology, invented and developed by company president and founder Anil R.
Diwan, PhD. The company holds an exclusive, worldwide license to this
technology for its antiviral drugs. The technology is protected by two broad
international patent applications that cover compositions of matter, processes
of manufacture, methods of use, and fields of use. Additional patent
applications are expected, and NanoViricides intends to patent each drug
separately, as well.
NanoViricides works with independent researchers at leading
academic, private, and government laboratories, performing tests against viral
targets, and providing unbiased data on drug candidates. In addition to drug
development, the company has put together a world-class team to design, build,
and validate a state-of-the-art manufacturing facility for the production of
human clinical batches of nanoviricide drug substances.
For more information, visit www.NanoViricides.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
